Form 4: Rigel CFO Granted 20,636 Restricted Stock Units

Rigel Pharmaceuticals' EVP & CFO, Dean L. Schorno, was granted 20,636 Restricted Stock Units, vesting quarterly over three years starting March 31, 2026.

Summary

• Dean L. Schorno, EVP & Chief Financial Officer of Rigel Pharmaceuticals Inc. (RIGL), was granted 20,636 shares of common stock.
• These shares are in the form of Restricted Stock Units (RSUs) with a transaction date of February 17, 2026.
• The RSUs will vest quarterly over a three-year period, with the initial vesting scheduled for March 31, 2026.
• Following this grant, Mr. Schorno's direct beneficial ownership of common stock will be 76,337 shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a routine and generally positive event, reflecting standard executive compensation practices aimed at retaining key talent and aligning management's interests with long-term shareholder value.

Positives

• The grant of Restricted Stock Units to the EVP & CFO aligns management's interests with long-term shareholder value.
• The three-year vesting schedule promotes executive retention and sustained performance.

Future Outlook

The vesting schedule for the Restricted Stock Units extends over three years, indicating a long-term incentive structure for the EVP & CFO, aligning future performance with compensation.

Industry Context

StockSavvy.ai notes that granting Restricted Stock Units is a common practice in the biotechnology and pharmaceutical industry to incentivize key executives, aligning their compensation with the company's long-term performance and shareholder interests. This practice is standard for retaining talent in a competitive sector.

Comparison to Industry Standards

• The grant of RSUs with a multi-year vesting schedule is a standard executive compensation practice across the pharmaceutical and biotech sectors, comparable to incentive structures at companies like Amgen, Gilead Sciences, and Biogen, which also utilize long-term equity awards to retain and motivate senior leadership.
• The specific number of units granted to a CFO would typically be benchmarked against peer companies of similar market capitalization and stage of development, though this filing does not provide such comparative data.

Stakeholder Impact

• Shareholders: Potentially positive due to increased alignment of executive interests with long-term company performance.
• Employees: No direct impact mentioned, but could signal stability in executive leadership.

Next Steps

• Quarterly vesting of the 20,636 Restricted Stock Units over the next three years, commencing March 31, 2026.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation event (RSU grant) and does not contain information that would fundamentally alter the investment thesis for Rigel Pharmaceuticals. It reinforces management's long-term alignment but does not provide new operational or financial data to warrant a change in existing investment posture.

Keywords

Rigel Pharmaceuticals, RIGL, Form 4, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Dean L. Schorno, CFO